1.在除MTX外的其他DMARD基础上加激素（如激素+柳氮磺吡啶），与激素+MTX及生物制剂+MTX的疗效对比情况如何？

2.不同生物制剂加MTX治疗活动性类风湿关节炎的疗效有无不同？

3.对TNF抑制剂无效或丧失疗效的RA患者使用其他生物制剂的疗效有无差别？

4.在持续缓解的患者能否停用生物制剂? 与停激素+MTX或停激素相比，停生物制剂会出现怎样的情况？

5.对于长期缓解的患者，逐步停用生物和非生物性DMARD药物的最佳途径是什么？

6.以MTX+激素，多种非生物性DMARD（含MTX）联合+激素，多种非生物性DMARD（含MTX）联合（无激素），以及生物制剂+MTX联合作为开始治疗策略，有何不同？

7.以新定义的ACR/EULAR缓解标准为治疗目标，与以获得低度病情活动为治疗目标间的临床、功能和放射性有何大的不同？

8.能否找到提示非生物性和生物性DMARD有效的指标？

9.在MTX或MTX+SSZ方案基础上，增加抗疟药有何疗效？

10. 病情快速进展高风险的RA患者使用生物制剂的效价比是否好于非生物制剂加激素？

附原文：

Research agenda

1.What is the efficacy of GCs when added to DMARDs other than MTX or combinations of synthetic DMARDs with MTX, such as GC plus SSZ, compared with GC plus MTX and biological agents+MTX?

2.How comparable or different is the efficacy of the various biological agents in patients with active disease despite MTX?

3.How comparable or different is the efficacy of the various biological agents in patients who did not respond or lost response to TNF inhibitors?

4.Can biological agents be stopped in sustained remission with maintenance of remission, and how does stopping biological agents compare with stopping GC plus MTX or stopping GC?

5.What is the best way to taper treatment with synthetic and biological DMARDs in patients with longstanding remission? (comparison of different tapering ways)

6.Which differences will exist when comparing treatment strategies starting in parallel with MTX monotherapy plus GC, combination of synthetic DMARDs including MTX plus GC, combination of synthetic DMARDs including MTX without GC and biological agents plus MTX?

7.How big is the difference of clinical, functional, radiographic efficacy when a treatment strategy aiming at remission by newly defined ACR/EULAR remission criteria is compared with a strategy aiming at achievement of low disease activity?

8.Can we find predictors of response to synthetic DMARDs and different biological agents?